Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 4, 2022

Rhea-AI Summary

Asensus Surgical (ASXC) will release its Q1 2022 financial and operational results on May 4, 2022, post-market. A conference call is scheduled at 4:30 p.m. ET to discuss the results, which will also be available via webcast. The company focuses on digitizing surgery through its Senhance Surgical System and aims to enhance surgical outcomes with advanced technologies like machine vision and deep learning. The system is currently available for sale in the US, EU, Japan, and select countries.

Positive

• Plans to release Q1 2022 results on May 4, 2022, potentially signaling transparency and investor engagement.
• Focus on innovative technology with the Senhance Surgical System, which aims to improve surgical outcomes.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 first quarter financial and operating results after the market closes on Wednesday, May 4, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial 1-877-407-9716 for domestic callers and 1-201-493-6779 for international callers, and reference conference ID 13728750 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005065/en/

INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499

invest@asensus.com

or

MEDIA CONTACT:

Kristin Schaeffer, 858-354-8850

CG Life

kschaeffer@cglife.com

Source: Asensus Surgical, Inc.

FAQ

When will Asensus Surgical release its Q1 2022 results?

Asensus Surgical will release its Q1 2022 financial results on May 4, 2022.

What time is the Asensus Surgical conference call for Q1 2022 results?

The conference call for Asensus Surgical's Q1 2022 results is scheduled for 4:30 p.m. ET on May 4, 2022.

How can I listen to Asensus Surgical's earnings call?

You can listen to the earnings call by dialing 1-877-407-9716 for domestic callers or 1-201-493-6779 for international callers, and referencing conference ID 13728750.

What is the focus of Asensus Surgical?

Asensus Surgical focuses on digitizing the interface between surgeons and patients to enhance surgical outcomes using advanced technologies.

In which markets is the Senhance Surgical System available?

The Senhance Surgical System is available for sale in the US, EU, Japan, and select other countries.